Please use this identifier to cite or link to this item: http://hdl.handle.net/10397/30939
Title: Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor-dependent osteoblastic functions in UMR 106 cells
Authors: Mok, SK
Chen, WF
Lai, WP
Leung, PC
Wang, XL
Yao, XS
Wong, MS 
Keywords: BMD
Estrogen receptors
Icariin
Osteoprotegerin
RANKL
Issue Date: 2010
Publisher: Wiley-Blackwell
Source: British journal of pharmacology, 2010, v. 159, no. 4, p. 939-949 How to cite?
Journal: British journal of pharmacology 
Abstract: Background and purpose: Icariin may be the active ingredient in Herba Epimedii, a Chinese herb commonly used for treatment of osteoporosis. The present study aims to delineate the mechanism(s) by which icariin prevents bone loss after ovariectomy (OVX) in vivo and stimulates osteoblastic functions in vitro. Experimental approach: Ovariectomized or sham-operated C57BL/6 mice were treated with vehicle, 17-oestradiol or icariin for 6 weeks. Total and trabecular bome mineral density (BMD) as well as polar stress-strain index of distal femur were measured by peripheral computed tomography. The mRNA expressions of OPG and RANKL in tibia were studied by RT-PCR. Interactions between the oestrogen receptor (ER) antagonist ICI182,780 and icariin were studied in UMR 106 cells. The functional transactivation of ER and ER as well as ER phosphorylation by icariin were also assessed. Key results: Icariin suppressed the loss of bone mass and strength in distal femur and increased the mRNA expression ratio of OPG/RANKL in tibia, following OVX. Icariin increased ER-dependent cell proliferation, alkaline phosphatase (ALP) activity, gene expression of OPG and the OPG/RANKL ratio in UMR 106 cells. Icariin did not activate ERE-luciferase activity in UMR 106 cells, via the ER or the ER-mediated pathway, but it did increase ER phosphorylation at Ser118. Conclusions and implications: Our results indicate that icariin exerts anabolic effects in bone possibly by activating ER in a ligand-independent manner. Its ability to prevent OVX-induced bone loss without inducing uterotrophic effects supports its use as an alternative regimen for management of postmenopausal osteoporosis.
URI: http://hdl.handle.net/10397/30939
ISSN: 0007-1188
EISSN: 1476-5381
DOI: 10.1111/j.1476-5381.2009.00593.x
Appears in Collections:Journal/Magazine Article

Access
View full-text via PolyU eLinks SFX Query
Show full item record

SCOPUSTM   
Citations

83
Last Week
0
Last month
1
Citations as of Dec 3, 2017

WEB OF SCIENCETM
Citations

72
Last Week
0
Last month
0
Citations as of Dec 9, 2017

Page view(s)

62
Last Week
5
Last month
Checked on Dec 11, 2017

Google ScholarTM

Check

Altmetric



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.